The use of digital pathology and image analysis in clinical trials

Digital pathology and image analysis potentially provide greater accuracy, reproducibility and standardisation of pathology‐based trial entry criteria and endpoints, alongside extracting new insights from both existing and novel features. Image analysis has great potential to identify, extract and q...

Full description

Saved in:
Bibliographic Details
Published inThe journal of pathology. Clinical research Vol. 5; no. 2; pp. 81 - 90
Main Authors Pell, Robert, Oien, Karin, Robinson, Max, Pitman, Helen, Rajpoot, Nasir, Rittscher, Jens, Snead, David, Verrill, Clare, Driskell, Owen J, Hall, Andy, James, Jacqueline, Jones, Louise J, Craig, Clare, Sloan, Philip, Thomas, Gareth J, Elliott, Philip, Cheang, Maggie, Rodriguez‐Justo, Manuel, Rees, Gabrielle, Salto‐Tellez, Manuel, West, Nicholas P, Mirabile, Ilaria, Howlett, Emily, Stevenson, Laura, da Silva, Maria, Hartridge‐Lambert, Sidonie, Beecham, Joseph M, Traub, Stephanie, Katugampola, Sidath, Blagden, Sarah, Morden, James
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.04.2019
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Digital pathology and image analysis potentially provide greater accuracy, reproducibility and standardisation of pathology‐based trial entry criteria and endpoints, alongside extracting new insights from both existing and novel features. Image analysis has great potential to identify, extract and quantify features in greater detail in comparison to pathologist assessment, which may produce improved prediction models or perform tasks beyond manual capability. In this article, we provide an overview of the utility of such technologies in clinical trials and provide a discussion of the potential applications, current challenges, limitations and remaining unanswered questions that require addressing prior to routine adoption in such studies. We reiterate the value of central review of pathology in clinical trials, and discuss inherent logistical, cost and performance advantages of using a digital approach. The current and emerging regulatory landscape is outlined. The role of digital platforms and remote learning to improve the training and performance of clinical trial pathologists is discussed. The impact of image analysis on quantitative tissue morphometrics in key areas such as standardisation of immunohistochemical stain interpretation, assessment of tumour cellularity prior to molecular analytical applications and the assessment of novel histological features is described. The standardisation of digital image production, establishment of criteria for digital pathology use in pre‐clinical and clinical studies, establishment of performance criteria for image analysis algorithms and liaison with regulatory bodies to facilitate incorporation of image analysis applications into clinical practice are key issues to be addressed to improve digital pathology incorporation into clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Joint senior authors. Both authors contributed equally to the manuscript.
CV, DS, NR and JR are part of the PathLAKE digital pathology consortium. These new Centres are supported by a £50m investment from the Data to Early Diagnosis and Precision Medicine strand of the government's Industrial Strategy Challenge Fund, managed and delivered by UK Research and Innovation (UKRI).
The members of the NCRI CM‐Path Quality Assurance Panel are listed in the Acknowledgements section.
ISSN:2056-4538
2056-4538
DOI:10.1002/cjp2.127